Collectively, these data demonstrate that SB225002 inhibits CXCR2 at both the transcriptional and protein levels, thereby blocking CXCR2-driven oncogenic signaling and suppressing NB growth. This evidence concerns the gene CXCR2 and neuroblastoma.